ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,948Medicare Part D Prescriptions Filled, Including Refills

Rank: 36 out of 623

$550K Total Retail Price of All Prescriptions

Rank: 31 out of 623

351 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
68% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 351 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

8% of this provider’s 351 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 6,694 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$69 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
FUROSEMIDE 258 246 1 5
LEVOTHYROXINE SODIUM 236 225 2 4
AMLODIPINE BESYLATE 204 181 3 3
LISINOPRIL 183 162 4 1
PRAVASTATIN SODIUM 167 153 5 11
MIRTAZAPINE 162 124 6 31
OMEPRAZOLE 161 151 7 7
SIMVASTATIN 153 112 8 2
TRAMADOL HCL 147 117 9 15
ATENOLOL 135 130 10 12
METOPROLOL TARTRATE 125 124 11 9
MELOXICAM 118 98 12 50
DONEPEZIL HCL 117 117 13 27
CITALOPRAM HBR 103 95 14 21
ATORVASTATIN CALCIUM 100 93 15 10
GABAPENTIN 94 72 16 18
METOPROLOL SUCCINATE 85 85 17 13
SERTRALINE HCL 84 84 18 20
METFORMIN HCL 82 76 19 6
PANTOPRAZOLE SODIUM 82 71 19 26
GLIMEPIRIDE 77 73 21 38
HYDROCHLOROTHIAZIDE 77 61 21 8
POTASSIUM CHLORIDE 75 71 23 24
RANITIDINE HCL 75 71 23 23
LOSARTAN POTASSIUM 75 69 23 16
ENALAPRIL MALEATE 70 56 26 73
ALLOPURINOL 68 62 27 44
TRAZODONE HCL 67 55 28 36
ZOLPIDEM TARTRATE 65 46 29 22
CRESTOR 60 41 30 28
METFORMIN HCL ER 60 49 30 56
SUBOXONE 57 0 32 85
RISPERIDONE 53 43 33 49
LIDODERM 53 52 33 82
ALENDRONATE SODIUM 52 52 35 37
POLYETHYLENE GLYCOL 3350 50 50 36 53
MECLIZINE HCL 50 40 36 174
NAMENDA 50 50 36 47
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 12, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.